CNS Drugs

, Volume 22, Issue 4, pp 325–334 | Cite as

Pregnancy Outcome after In Utero Exposure to Valproate

Evidence of Dose Relationship in Teratogenic Effect
  • Orna Diav-Citrin
  • Svetlana Shechtman
  • Benjamin Bar-Oz
  • Dana Cantrell
  • Judy Arnon
  • Asher Ornoy
Original Research Article

Abstract

Background: Valproate is a first-line antiepileptic agent and is also used in the treatment of bipolar disorder and migraine. It is a known human teratogen. The objective of the study was to evaluate the teratogenic risk of valproate.

Methods: All callers who contacted the Israeli Teratology Information Service (TIS) between 1994 and 2004 for information about gestational exposure to valproate were enrolled in the study. After the expected date of delivery, these women were followed up by telephone interview about their pregnancy outcome using a structured questionnaire. Data obtained from women who contacted the TIS about valproate exposure during pregnancy were then compared with data obtained from callers who were counselled for nonteratogenic exposures over the same timeframe. The main outcome measure was the rate of major congenital anomalies.

Results: The outcomes of 154 valproate-exposed pregnancies (96.1% at least in the first trimester) were compared with those of 1315 pregnancies of women in the TIS database who were counselled for nonteratogenic exposures. The rate of major anomalies (some multiple) in the valproate group exposed in the first trimester was higher compared with controls after exclusion of genetic or cytogenetic anomalies (8 of 120 [6.7%] vs 31 of 1236 [2.5%], p = 0.018, relative risk [RR] = 2.66, 95% CI 1.25, 5.65). There were no cases of neural tube defect in the valproate-exposed group. Five of the eight major anomalies in the valproate group were cardiovascular, two of eight were mentally retarded, two of five male infants with major anomalies had hypospadias and three of eight were suspected of having fetal valproate syndrome. A daily dose ≥1000 mg was associated with the highest teratogenic risk (7 of 32 [21.9%] vs 31 of 1236 [2.5%], RR = 8.72, 95% CI 4.16, 18.30). In the subgroup exposed to polytherapy there was a 4-fold increase in the rate of major anomalies compared with controls. All major anomalies were in the group treated for epilepsy.

Conclusion: When valproate treatment cannot be avoided in the first trimester of pregnancy, the lowest effective dose should be prescribed, preferably as monotherapy, to minimize its teratogenic risk.

References

  1. 1.
    Schardein JL, ed. Chemically induced birth defects. New York: Marcel Dekker, Inc., 1993Google Scholar
  2. 2.
    Brown NA, Kao J, Fabro S. Teratogenic potential of valproic acid. Lancet 1980; 1: 660–1PubMedCrossRefGoogle Scholar
  3. 3.
    Dalens B, Raynaud EJ, Gaulme J. Teratogenicity of valproic acid. J Pediatr 1980; 97: 332–3PubMedGoogle Scholar
  4. 4.
    Gomez MR. Possible teratogenicity of valproic acid. J Pediatr 1981; 98: 508–9PubMedGoogle Scholar
  5. 5.
    Stanley OH, Chambers TL. Sodium valproate and neural tube defects [letter]. Lancet 1982; 2: 1282CrossRefGoogle Scholar
  6. 6.
    Blaw ME, Woody RC. Valproic acid embryopathy [letter]. Neurology 1983; 33: 255PubMedCrossRefGoogle Scholar
  7. 7.
    Centers for Disease Control (CDC). Valproic acid and spina bifida: a preliminary report — France. MMWR Morb Mortal Wkly Rep 1982; 31: 565–6Google Scholar
  8. 8.
    Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects [letter]. Lancet 1982; 2: 937PubMedCrossRefGoogle Scholar
  9. 9.
    Bjerkedal T, Czeizel A, Goujard J, et al. Valproic acid and spina bifida [letter]. Lancet 1982; 2: 1096PubMedCrossRefGoogle Scholar
  10. 10.
    Omtzigt JG, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992; 42: 119–25PubMedGoogle Scholar
  11. 11.
    DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984; 19: 473–81PubMedCrossRefGoogle Scholar
  12. 12.
    Ardinger HH, Atkin JF, Blackston RD, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29: 171–85PubMedCrossRefGoogle Scholar
  13. 13.
    Bertollini R, Kallén B, Mastroiacovo P, et al. Anticonvulsant drugs in monotherapy: effect on the fetus. Eur J Epidemiol 1987; 3: 164–71PubMedCrossRefGoogle Scholar
  14. 14.
    Rodriguez-Pinilla E, Arroyo I, Fondevilla J, et al. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. Am J Med Genet 2000; 90: 376–81PubMedCrossRefGoogle Scholar
  15. 15.
    Wide K, Winbladh B, Kallén B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93: 174–6PubMedCrossRefGoogle Scholar
  16. 16.
    Wyszynski DF, Nambisan M, Surve T, et al., on behalf of the Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961–5PubMedCrossRefGoogle Scholar
  17. 17.
    Martinez-Frias ML, Rodriguez-Pinilla E, Salvador J. Valproate and spina bifida [letter]. Lancet 1989; 1: 611–2Google Scholar
  18. 18.
    Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992; 42Suppl. 5: 75–82PubMedGoogle Scholar
  19. 19.
    Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38: 981–90PubMedCrossRefGoogle Scholar
  20. 20.
    Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60: 575–9PubMedCrossRefGoogle Scholar
  21. 21.
    Vajda FJ, O’Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004; 11: 854–8PubMedCrossRefGoogle Scholar
  22. 22.
    Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005; 64: 1874–8PubMedCrossRefGoogle Scholar
  23. 23.
    Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193–8PubMedCrossRefGoogle Scholar
  24. 24.
    Meador KJ, Baker GA, Finnell RH, et al., on behalf of the NEAD Study Group. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006; 67: 407–12PubMedCrossRefGoogle Scholar
  25. 25.
    Koren G, Nava-Ocampo AA, Moretti ME, et al. Major malformations with valproic acid. Can Fam Physician 2006; 52: 441–7PubMedGoogle Scholar
  26. 26.
    Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000; 37: 489–97PubMedCrossRefGoogle Scholar
  27. 27.
    Dean JC, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002; 39: 251–9PubMedCrossRefGoogle Scholar
  28. 28.
    Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1575–83PubMedCrossRefGoogle Scholar
  29. 29.
    Yerby MS. Pregnancy, teratogenesis, and epilepsy. Neurol Clin 1994; 12: 749–71PubMedGoogle Scholar
  30. 30.
    Lindhout D, Omtzigt JG. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 1994; 35Suppl. 4: S19–28PubMedCrossRefGoogle Scholar
  31. 31.
    Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988; 29: 459–67PubMedCrossRefGoogle Scholar
  32. 32.
    Holmes LB. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies [editorial]. Teratology 1999; 59: 1–2PubMedCrossRefGoogle Scholar
  33. 33.
    Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972; 2: 839–43PubMedCrossRefGoogle Scholar
  34. 34.
    Bjerkedal T, Bahna SL. The course and outcome of pregnancy in women with epilepsy. Acta Obstet Gynecol Scand 1973; 52: 245–8PubMedCrossRefGoogle Scholar
  35. 35.
    Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976; 1: 272–5PubMedCrossRefGoogle Scholar
  36. 36.
    Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy. Drug Saf 2004; 27: 197–202PubMedCrossRefGoogle Scholar
  37. 37.
    Laegreid L, Kyllerman M, Hedner T, et al. Benzodiazepine amplification of valproate teratogenic effects in children of mothers with absence epilepsy. Neuropediatrics 1993; 24: 88–92PubMedCrossRefGoogle Scholar
  38. 38.
    Zlotogora J, Amitai Y, Nitzan Kaluski D, et al. Data from the National NTD Registry in Israel [letter]. BMJ 2005 [online]. Available from URL: http://bmj.bmjjournals.com/cgi/eletters/330/7491/571 [Accessed 2008 Jan 23]
  39. 39.
    Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia 2000; 41: 1436–43PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Orna Diav-Citrin
    • 1
  • Svetlana Shechtman
    • 1
  • Benjamin Bar-Oz
    • 2
  • Dana Cantrell
    • 3
  • Judy Arnon
    • 1
  • Asher Ornoy
    • 1
    • 3
  1. 1.The Israeli Teratology Information Service, Israel Ministry of Health and Laboratory of Teratology, Department of Anatomy and Cell BiologyThe Hebrew University Hadassah Medical SchoolJerusalemIsrael
  2. 2.The Department of NeonatologyHadassah and Hebrew University Medical CenterJerusalemIsrael
  3. 3.The Hebrew University and Hadassah Medical SchoolJerusalemIsrael

Personalised recommendations